Does Ascorbic Acid Reduce Sympathoexcitation in CHF?

Not Applicable

Completed

• Conditions: Heart Failure
• Interventions: Drug: placebo; Drug: vitamin C

• Registration Number: NCT00550121
• Lead Sponsor: Radboud University Medical Center

Brief Summary

In CHF central sympathetic activity is increased. ROS formation seems to play a role in this process. This study analyzes the effect of vitamin C as an antioxidant on central sympathetic activity in CHF

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08
• Study First Submitted: 2007-10-25
• Study First Submitted QC: 2007-10-25
• Study First Posted: 2007-10-26
• Study Completion: 2008-04
• Status Verified: 2008-10
• Last Update Submitted: 2008-10-13
• Last Update Posted: 2008-10-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Heart failure of at least New York Heart Association (NYHA) class II
• Left ventricular ejection fraction (LVEF) <= 40%
• Age 20-80 years

Exclusion Criteria

• Necessity of short-term PCI, CABG or heart transplantation,
• Chronic disease of the autonomic nervous system,
• diabetes mellitus,
• use of tricyclic antidepressant drugs and/or a-adrenergic receptor antagonists.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
2	placebo	-
1	vitamin C	-

Primary Outcome Measures

Name	Time	Method
change in central sympathetic output after vitamin C vs. placebo

Trial Locations

Locations (1)

Radboud University Nijmegen Medical Centre; 🇳🇱 Nijmegen, Netherlands